Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
04 June 2021 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2021 (No. 1)
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive
offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
The Chief Financial Officer, Eyal Leibovitz, of Cellect Biotechnology
Ltd. (the “Company”) will terminate his service with the Company as its CFO. Mr. Leibovitz will maintain his primary responsibilities
as CFO, per the Company’s request, through August 31, 2021, by which time the Company anticipates its strategic merger with privately-held
Quoin Pharmaceuticals, Inc. will have closed.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
CELLECT BIOTECHNOLOGY, LTD.
|
|
|
Date: June 3, 2021
|
By:
|
/s/ Shai Yarkoni
|
|
|
Shai Yarkoni
Chief Executive Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2024 to May 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cellect Biotechnology Ltd (NASDAQ): 0 recent articles
More Cellect Biotechnology Ltd. News Articles